Horowitz, Mark Abie
Framer, Adele
Hengartner, Michael P.
Sørensen, Anders
Taylor, David https://orcid.org/0000-0002-2557-1710
Article History
Accepted: 20 September 2022
First Online: 14 December 2022
Declarations
:
: This paper was not supported by any funding. Mark Abie Horowitz is supported by a Clinical Research Fellowship through the North East London NHS Foundation Trust. This funding source had no role in the writing of the manuscript or the decision to submit it for publication. MAH is an honorary Clinical Research Fellow at UCL. The Psychiatry Research Trust funded the open access publication of this article. This funder was not involved in the planning or writing of the manuscript, or decision to submit for publication.
: Anders Sørensen has no conflicts of interest. Mark Abie Horowitz declares that he is a co-founder of Outro Health, a company aiming to help people safely stop unnecessary antidepressants in Canada and North America. Adele Framer declares she is a co-founder of Outro Health. Michael P. Hengartner reports royalties from Palgrave Macmillan, London, UK for his book published in December, 2021, called “Evidence-biased Antidepressant Prescription.” David Taylor reports grants and personal fees from Janssen, Sunovion, Recordati and Mylan, and personal fees from Accord, outside the submitted work.
: Not applicable.
: Not applicable.
: Not applicable.
: All data in this study are available in the public domain.
: Not applicable.
: MAH conceived the idea of the manuscript, conducted the searches and wrote the first draft. MPH performed the data analysis and contributed substantially to the manuscript. AF further developed the concepts of the paper and substantially contributed to the final form of the manuscript. AS and DT revised and contributed substantially to the final form of the manuscript. DT supervised the project. All authors have read and approve the final submitted manuscript and all agree to be accountable for the work.